Medtronic cardiovascular organic growth in Q1
Short Answer
The model assigns meaningfully higher odds than the market for Medtronic's cardiovascular organic growth in Q1 to be Above 6% (24.7% model vs 0.0% market). This is driven by Medtronic's Q1 FY2027 overall organic revenue growth guidance of 11.5% to 12.0%, significantly boosted by an extra selling week, and the Cardiovascular segment's consistent historical outperformance.
1. Executive Verdict
- Medtronic's Q1 FY2027 cardiovascular growth above 6% is likely, given 11.5-12.0% overall guidance.
- The segment historically outperforms company growth, further boosted by an extra Q1 selling week.
- Strong product drivers like Cardiac Ablation Solutions are expected to support robust performance.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 12% | 6.0% | 9.0% | Medtronic's Q1 FY2027 guidance and historical outperformance suggest robust cardiovascular growth. |
| Above 10% | 0.0% | 18.0% | Medtronic's Q1 FY2027 guidance and historical outperformance suggest robust cardiovascular growth. |
| Above 11% | 0.0% | 14.0% | Medtronic's Q1 FY2027 guidance and historical outperformance suggest robust cardiovascular growth. |
| Above 6% | 0.0% | 24.7% | Medtronic's Q1 FY2027 guidance and historical outperformance suggest robust cardiovascular growth. |
| Above 7% | 0.0% | 24.0% | Medtronic's Q1 FY2027 guidance and historical outperformance suggest robust cardiovascular growth. |
Current Context
Medtronic's Q1 FY2027 cardiovascular growth is not yet reported. As of August 9, 2026, Medtronic has not released its Q1 FY2027 financial results; consequently, the cardiovascular organic revenue growth figure for this period is unavailable [^][^][^][^][^][^]. The company is scheduled to report its Q1 FY2027 results on Tuesday, September 1, 2026, at 5:45 a.m. Central Time, with a webcast following at 6:45 a.m. Central Time [^][^]. The first fiscal quarter concluded on Friday, July 31, 2026 [^].
Overall Q1 FY2027 organic growth guidance is available, not cardiovascular. Medtronic's FY2027 organic revenue growth guidance includes an approximate 11.5% to 12.0% organic growth for the first quarter overall, as stated in FY2026 Q4 materials [^][^]. However, the company has not explicitly provided a separate Q1 FY2027 cardiovascular organic revenue growth figure [^]. For historical context, the most recently reported cardiovascular organic growth was 7.00% in Q1 FY2026 [^][^][^][^][^][^]. Medtronic's cardiovascular segment delivered 10.10% organic growth in Q4 FY2026, driven by factors such as CAS growth and the expanded CE Mark for Affera/Sphere-9 in ventricular arrhythmias [^][^][^][^][^][^][^][^]. An external market is available for "Above 9% cardiovascular organic revenue growth in Q1 2027", but this is not an official company KPI [^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This market's price action displays a dramatic, near-vertical increase over a two-day period. The implied probability of Medtronic's Q1 FY2027 cardiovascular organic growth meeting the market's criteria moved from a low of 1.0% on August 7, 2026, to 94.0% by August 9, 2026. This represents an almost complete reversal in outlook. The provided context, however, offers no clear catalyst for this extreme price movement, as it primarily notes that the relevant financial data has not yet been released.
The most critical feature of this market is the complete absence of trading volume. With zero contracts traded, the price changes reflect shifts in unfilled bids and asks, not executed transactions. This indicates a highly illiquid market with no active participation or capital commitment behind the price levels shown. The lack of volume means traditional technical indicators like support and resistance levels are not meaningful.
The chart's price trajectory suggests a rapid shift in sentiment from overwhelmingly negative to highly positive. However, this reading is superficial. Given the zero-volume environment, the price cannot be interpreted as a reliable consensus forecast. It likely reflects the actions of a single participant setting an initial low offer and then a subsequent high bid, without any counter-party engaging to establish a traded price. The market is effectively unformed.
3. Market Data
Contract Snapshot
For a given percentage threshold, a YES resolution occurs if Medtronic's cardiovascular organic growth in Q1 is strictly above that specified percentage. A NO resolution occurs if the growth is at or below the specified percentage. The market closes for trading on September 1, 4:00 PM EDT, with a maximum payout date of December 29, 2026. The provided content does not detail specific data sources or additional settlement conditions.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 12% | $0.06 | $0.99 | 6% |
| Above 10% | $0.22 | $0.85 | 0% |
| Above 11% | $0.10 | $0.97 | 0% |
| Above 6% | $0.99 | $0.06 | 0% |
| Above 7% | $0.94 | $0.13 | 0% |
| Above 8% | $0.74 | $0.33 | 0% |
| Above 9% | $0.45 | $0.62 | 0% |
Market Discussion
Medtronic's cardiovascular organic growth was 7.0% in Q1 FY2026, significantly boosted by nearly 50% revenue growth in its Cardiac Ablation Solutions (CAS) segment, largely attributed to pulsed field ablation products [^][^][^]. For Q1 FY2027, the company has announced guidance for approximately 11.5% to 12% organic growth, a projection analysts support, citing continued CAS momentum and strategic investments made in June 2026 [^][^][^]. Current market odds suggest a 70% chance of growth exceeding 8% [^].
4. How did Medtronic's cardiovascular growth in the most recent reported quarter compare to that of its key competitors, Boston Scientific and Abbott Laboratories?
| Medtronic Cardiovascular Growth | 10.1% organic revenue growth (Q4 FY26) [^][^][^][^][^] |
|---|---|
| Boston Scientific Cardiovascular Growth | 7.8% organic revenue growth (Q2 2026) [^][^][^][^][^] |
| Abbott Medical Devices Growth | 8.4% comparable sales growth (Q2 2026) [^][^][^][^] |
Medtronic's cardiovascular growth exceeded Boston Scientific's in recent quarters. Medtronic's cardiovascular portfolio achieved 10.1% organic revenue growth in its most recent reported quarter, Q4 fiscal year 2026, which concluded on April 24, 2026 [^][^][^][^][^]. This performance outpaced Boston Scientific's cardiovascular segment, which reported 7.8% organic revenue growth in its most recent reported quarter, Q2 2026, ending June 30, 2026 [^][^][^][^][^]. Medtronic's Q1 fiscal year 2027 cardiovascular organic revenue growth is not yet reported as of August 9, 2026, though the company anticipates reaching $2 billion in trailing revenue during that quarter [^][^][^].
Comparing Abbott's diverse cardiovascular segments directly is challenging. Abbott Laboratories does not report a consolidated 'Cardiovascular' revenue growth figure [^][^][^][^]. Instead, Abbott reports growth for individual medical device businesses. For example, Electrophysiology saw 13.4% comparable sales growth, and Rhythm Management grew 9.5% in Q2 2026. Abbott's broader Medical Devices segment collectively grew 8.4% on a comparable basis during its most recent reported quarter, Q2 2026 [^][^][^][^].
5. How has Medtronic's Cardiovascular segment growth historically performed relative to the company's overall organic growth guidance for the same quarter?
| Cardiovascular Segment Organic Growth (Q4 FY26) | 10.1% [^][^][^] |
|---|---|
| Overall Company Organic Growth (Q4 FY26) | 6.6% [^][^][^] |
| Full-Year FY27 Organic Revenue Growth Guidance | 6.75% to 7.25% [^][^][^] |
Medtronic's Cardiovascular segment consistently outperforms overall company organic revenue growth. In recent quarters, the Cardiovascular segment has shown stronger organic revenue growth compared to the company's overall performance [^][^][^]. For instance, in Q4 FY26, the Cardiovascular segment achieved 10.1% organic growth, significantly surpassing the company's overall organic revenue growth of 6.6% during the same period [^][^][^].
Quarterly organic growth guidance for past periods remains unspecified. While the Cardiovascular segment demonstrates a strong recent track record, specific details regarding its historical growth performance relative to Medtronic's overall organic growth guidance for any given quarter are not available [^][^][^]. Medtronic has issued full-year FY27 organic revenue growth guidance of 6.75% to 7.25%, which accounts for a 53rd week and the full-year consolidation of the Diabetes business. However, the provided information does not include the company's overall organic growth guidance for past quarters, such as Q4 FY26, or for the upcoming Q1 FY2027 [^][^][^].
6. Which specific product lines or recent regulatory approvals within Medtronic's cardiovascular portfolio are expected to be the primary growth drivers in Q1 FY2027?
| CAS global revenue growth Q4 FY2026 | 78% [^][^][^] |
|---|---|
| CAS annualized revenue target Q1 FY2027 | over $2 billion [^][^][^] |
| Medtronic Q1 FY2027 organic revenue growth guidance | approximately 11.5% to 12.0% [^][^][^][^] |
Medtronic’s cardiovascular portfolio anticipates significant growth in Q1 FY2027. Primary growth drivers are expected from Cardiac Ablation Solutions (CAS), especially the Affera Mapping and Ablation System, which includes the Sphere-9 catheter [^][^][^][^]. Further momentum is anticipated from Micra leadless pacemakers, the OmniaSecure defibrillation lead, and the Symplicity renal denervation system [^][^][^][^]. Recent regulatory approvals for the Affera system and the OmniaSecure lead are also key contributors to this expected growth [^][^].
Cardiac Ablation Solutions are a major revenue growth engine. This segment delivered 78% global revenue growth in Q4 FY2026, with the company aiming to annualize over $2 billion in revenue in Q1 FY2027 [^][^][^]. A significant regulatory milestone supporting this growth is the expanded CE Mark for the Affera Mapping and Ablation System (Sphere-9) for ventricular arrhythmias, which was announced in August 2026 [^]. The OmniaSecure defibrillation lead also contributes significantly, having received FDA approval for its conduction system pacing indication in March 2026, making it the first lead of its kind [^].
Other product lines and approvals bolster overall growth projections. Micra leadless pacemakers are expected to provide continued momentum [^][^][^][^]. Additionally, the Mosaic Neo mitral bioprosthesis, which received FDA approval in April 2026, has seen rapid adoption across major US hospitals [^]. Medtronic has guided to Q1 FY2027 organic revenue growth of approximately 11.5% to 12.0% for the company as a whole, with the Cardiovascular portfolio anticipated to maintain strong performance [^][^][^][^].
7. What has been the historical trend of Medtronic's quarterly cardiovascular organic revenue growth from fiscal year 2024 through fiscal year 2026?
| FY2024 Cardiovascular Organic Revenue Growth | 5.0% [^][^] |
|---|---|
| FY2025 Cardiovascular Organic Revenue Growth | 6.3% [^][^][^][^] |
| FY2026 Cardiovascular Organic Revenue Growth | 9.3% [^] |
Medtronic's cardiovascular organic revenue growth showed an upward trend from FY2024 to FY2026. While quarterly growth rates varied across this period, the full year performance consistently improved. In fiscal year 2024, the full year organic revenue growth for Medtronic's Cardiovascular segment reached 5.0%, with specific quarterly growth rates including 6.2% in Q1 and 4.0% in Q4 [^][^].
Full-year growth rates significantly improved through fiscal years 2025 and 2026. Fiscal year 2025 saw the full year growth rate increase to 6.3%, supported by quarterly performances such as 7.0% in Q1 and 7.8% in Q4 [^][^][^][^]. This upward trend continued into fiscal year 2026, where the full year Cardiovascular organic revenue growth accelerated significantly to 9.3% [^]. This period featured strong quarterly growth, with Q1 at 7.0%, Q2 at 7.1%, Q3 reaching 10.6%, and Q4 at 10.1% [^][^][^][^].
8. What macroeconomic or healthcare industry-wide factors, such as hospital procedure volumes or reimbursement changes, could materially impact Medtronic's cardiovascular sales during Q1 FY2027?
| Foreign Exchange Tailwind (Q1 FY2027) | neutral to $50 million [^][^][^][^] |
|---|---|
| Tariffs Impact | $75 million (expected) [^][^][^] |
| Fuel/Transportation Costs Headwind | approximately 1% (expected) [^][^][^] |
Macroeconomic factors will significantly influence Medtronic's Q1 FY2027 financial performance. Medtronic projects a foreign exchange tailwind ranging from neutral to $50 million for the quarter ending July 31, 2026. However, this positive impact is expected to be offset by an anticipated $75 million impact from tariffs and an approximate 1% headwind stemming from elevated fuel and transportation costs, primarily associated with the Middle East conflict. These macroeconomic elements are expected to materially affect Medtronic's overall financial results, including its cardiovascular sales [^][^][^][^][^].
Hospital challenges persist, yet Medtronic's cardiovascular portfolio shows strong growth. Within the healthcare industry, hospitals continue to manage significant workforce pressures and rising operational costs. Despite a 2.6% increase in Medicare 2026 OPPS/ASC payment rates, hospitals still face ongoing financial strain due to underpayments by government payers [^][^][^]. These industry-wide operational and reimbursement challenges could affect hospital procedure volumes, potentially impacting Medtronic's cardiovascular sales. Despite these industry headwinds, Medtronic's cardiovascular portfolio is experiencing growth driven by market share gains in Cardiac Rhythm Management and Cardiac Ablation Solutions (CAS), with the company on track to achieve $2 billion in annual CAS revenue by Q1 FY2027 [^][^][^].
9. What Could Change the Odds
Key Catalysts
Key growth drivers for the quarter include the Cardiac Ablation Solutions (CAS) business, which is on track to reach $2 billion in trailing revenue in Q1 FY27 [^] [^] [^] . Additionally, an extra selling week is projected to contribute 500-600 basis points to Q1 FY27 growth [^][^][^]. Conversely, potential headwinds include a $75 million impact from tariffs in Q1 and a foreign exchange impact ranging from neutral to a $50 million tailwind [^][^].
As of 2026-08-09, the Q1 FY2027 cardiovascular organic revenue growth figure is not yet available, pending the September 1 release [^] [^] [^] [^] [^] [^] . The most recent reported cardiovascular performance was 10.1% organic revenue growth in Q4 FY2026 for the Cardiovascular Portfolio [^][^][^][^][^][^]. Prediction markets are tracking cardiovascular organic revenue growth thresholds, such as above 9%, for Q1 2027 [^]. Bullish catalysts include this recent cardiovascular momentum and the continued product expansion in electrophysiology, specifically the Affera/Sphere-9 indication expansion for ventricular arrhythmias [^][^][^][^][^][^].
Key Dates & Catalysts
- Expiration: December 30, 2026
- Closes: December 30, 2026
10. Decision-Flipping Events
- Trigger: Medtronic is expected to report its Q1 fiscal 2027 financial results on Tuesday, September 1, 2026 [^] [^] .
- Trigger: The quarter ended on July 31, 2026 [^] [^] .
- Trigger: The company guided to enterprise organic revenue growth of approximately 11.5% to 12.0% for the first quarter of fiscal year 2027 [^] [^] .
- Trigger: Key growth drivers for the quarter include the Cardiac Ablation Solutions (CAS) business, which is on track to reach $2 billion in trailing revenue in Q1 FY27 [^] [^] [^] .
12. Historical Resolutions
No historical resolution data available for this series.
